Groszmann R J
Am J Gastroenterol. 1987 Feb;82(2):107-13.
Portal hypertension is the result of increased flow and increased resistance in the portal system. Pharmacological therapy is aimed at altering these factors by the use of vasoconstrictors to reduce flow and vasodilators to decrease intrahepatic resistance. The current status of pharmacological agents to achieve these effects is reviewed.
门静脉高压是门静脉系统血流增加和阻力增加的结果。药物治疗旨在通过使用血管收缩剂减少血流和血管扩张剂降低肝内阻力来改变这些因素。本文综述了实现这些作用的药物的现状。
